Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Lederman · SciRah

Researcher profile · Semantic Scholar

S. Lederman

Share profile

S. Lederman — researcher profile on SciRah

h-index: 7
Works: 15
Citations: 745

Most-cited papers

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
T. Pieber, B. Bode, A. Mertens, Young Min Cho +90 more
2019The Lancet Diabetes and Endocrinology241 citations Open access
Semantic Scholar
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
S. Lederman, F. Ottery, Antonio Cano, N. Santoro +7 more
2023The Lancet186 citations
Semantic Scholar
A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
G. Fraser, S. Lederman, A. Waldbaum, R. Kroll +4 more
2020Menopause98 citations Open access
Semantic Scholar
Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
J. Schwebke, Ryan H. Sobel, J. Gersten, Steven A. Sussman +12 more
2021Clinical Infectious Diseases73 citations Open access
Semantic Scholar
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
K. Hardt, A. Vandebosch, J. Sadoff, Mathieu le Gars +284 more
2022Lancet. Infectious Diseases (Print)65 citations Open access
Semantic Scholar
Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
N. Santoro, A. Waldbaum, S. Lederman, R. Kroll +5 more
2020Menopause62 citations Open access
Semantic Scholar
A real-world comparison of the clinical and economic utility of OVA1 and CA125 in assessing ovarian tumor malignancy risk
Gerard P. Reilly, D. Gregory, D. Scotti, S. Lederman +4 more
2023Journal of Comparative Effectiveness Research11 citations Open access
Semantic Scholar
The neurokinin 3 receptor antagonist, fezolinetant, is effective in treatment of menopausal vasomotor symptoms: a randomized, placebo-controlled, double-blind, dose-ranging study
G. Fraser, S. Lederman, A. Waldbaum, Misun Lee +2 more
2019Maturitas4 citations
Semantic Scholar
Sustained Efficacy of Oteseconazole in Women with Recurrent Vulvovaginal Candidiasis
S. Lederman, Ryan Sobel, J. D. Sobel, S. Curelop +1 more
2025Journal of Women's Health3 citations Open access
Semantic Scholar
OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
G. Fraser, S. Lederman, A. Waldbaum, Misun Lee +2 more
2019Journal of the Endocrine Society3 citations Open access
Semantic Scholar
Hormone Therapy : What Are We Doing in 2019 ?
N. Santoro, A. Waldbaum, S. Lederman, G. Fraser +15 more
20192 citations
Semantic Scholar
The Effects of a Non-Hormonal NK3R Antagonist Nutritional Supplement on Joint Discomfort and Quality of Life Parameters in Peri- and Postmenopausal Females
Michaela Alesi, Laura Mason, Stephen Carbonneau, S. Lederman +5 more
2025Current Developments in Nutrition0 citations Open access
Semantic Scholar
ORAL LEUPROLIDE (Ovarest®) ACHIEVES PROFOUND SUPPRESSION OF ESTRADIOL AND PAIN RELIEF COMPARABLE TO THAT OF APPROVED INJECTABLE LEUPROLIDE FORMULATIONS IN WOMEN WITH ENDOMETRIOSIS AND PELVIC PAIN
Gary A. Shangold, A. Rubin, N. Kivel, F. G. Morgan +4 more
2023Fertility and Sterility0 citations
Semantic Scholar
The neurokinin 3 receptor antagonist, fezolinetant, is effective in treatment of menopausal vasomotor symptoms: responder analysis results from a randomized, placebo-controlled, double-blind, dose-ranging study
G. Fraser, S. Lederman, A. Waldbaum, James Young +2 more
2019Endocrine Abstracts0 citations
Semantic Scholar
THU0560 TNX-102 SL for The Treatment of fibromyalgia: Comparison of 30% Pain Responder Analysis with Omeract Draft Composite Responder Endpoint Analyses
R. Gendreau, Lesley M. Arnold, D. Clauw, J. Gendreau +3 more
20160 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Fraser×6
Invite
G. Fraser — researcher profile on SciRah
A. Waldbaum×6
Invite
A. Waldbaum — researcher profile on SciRah
L. Skillern×6
Invite
L. Skillern — researcher profile on SciRah
S. Ramael×6
Invite
S. Ramael — researcher profile on SciRah

×4

Invite

N. Santoro — researcher profile on SciRah

Invite

Misun Lee — researcher profile on SciRah

Invite

James Young — researcher profile on SciRah

Invite

B. Bode — researcher profile on SciRah

Invite

R. Thurston — researcher profile on SciRah

Invite

R. Kroll — researcher profile on SciRah

Steven A. Sussman×2

Invite

Steven A. Sussman — researcher profile on SciRah

C. Lademacher×2

Invite

C. Lademacher — researcher profile on SciRah